Physician profile
Michael Ahearn
NPI 1184687717
$1,127.34
in general payments reported to CMS, 2019-2025
27 companies · $61.04 in 2025
The $61.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $299 · 2021: $134 · 2022: $32.15 · 2023: $112 · 2024: $35.14 · 2025: $61.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.66 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.11 | 2019 | |
| Neurocrine Biosciences, INC. | $141.52 | 2019-2025 | |
| Abbott Laboratories | $114.29 | 2019-2024 | Freestyle Libre 2 |
| Pfizer INC. | $62.82 | 2019-2025 | |
| Abbvie INC. | $59.63 | 2021-2022 | |
| Amarin Pharma, INC. | $45.58 | 2019-2020 | |
| Eisai INC. | $44.50 | 2020 | |
| Astellas Pharma US INC | $42.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.10 | 2023 | Austedo Xr |
| Lilly USA, LLC | $37.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $36.69 | 2019 | |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Dexcom, INC. | $30.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.54 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.60 | 2019-2020 | |
| Exact Sciences Corporation | $25.97 | 2025 | The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $23.83 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.47 | 2024 | Caplyta |
| Melinta Therapeutics, LLC | $16.57 | 2019 | |
| Cmp Pharma, INC. | $15.66 | 2020 | |
| Esperion Therapeutics, INC. | $15.15 | 2021 | |
| Allergan, INC. | $15.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.60 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.30 | 2021 | |
| Acadia Pharmaceuticals INC | $12.42 | 2020 | |
| Circassia INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ahearn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.